Beam Therapeutics Inc BEAM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Trading Information
- Previous Close Price
- $20.94
- Day Range
- $20.56–21.93
- 52-Week Range
- $20.23–38.24
- Bid/Ask
- $20.70 / $20.81
- Shares Outstanding
- 103.50M
- Market Cap
- $2.17B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 16.16
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 540
- Website
- https://www.beamtx.com
Valuation
Metric | BEAM |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.48 |
Price/Sales | 16.16 |
Price/Cash Flow | — |
Price/Earnings
BEAM
Financial Strength
Metric | BEAM |
|---|---|
Quick Ratio | 12.72 |
Current Ratio | 13.00 |
Interest Coverage | — |
Quick Ratio
BEAM
Profitability
Metric | BEAM |
|---|---|
Return on Assets (Normalized) | −20.29% |
Return on Equity (Normalized) | −26.08% |
Return on Invested Capital (Normalized) | −24.49% |
Return on Assets
BEAM
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%<?@SJM | LOCK|@w%n! | $136B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|$DdrJrC | LOCK|%#rz< | $99B | |||
| Moderna Inc MRNA | LOCK|<Bf&Y^ | LOCK|X?$ | $87B | |||
| argenx SE ADR ARGX | LOCK|HK^>QxQ | LOCK|y>^ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|ys?@$Sy | LOCK|D# | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|!<<G!YL& | LOCK|$%X$ | $31B | |||
| Incyte Corp INCY | LOCK|>R><?>< | LOCK|W! | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|XGg!R% | LOCK|WNhy | $21B | |||
| BioNTech SE ADR BNTX | LOCK|%>!t%mM | LOCK|tm | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|#!Pz$l? | LOCK|^R@ | $15B |